Natera, Inc. $NTRA Holdings Trimmed by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH lowered its holdings in Natera, Inc. (NASDAQ:NTRA) by 5.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 120,636 shares of the medical research company’s stock after selling 6,545 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.09% of Natera worth $20,380,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Vanguard Group Inc. raised its position in Natera by 0.6% during the first quarter. Vanguard Group Inc. now owns 12,393,827 shares of the medical research company’s stock valued at $1,752,611,000 after buying an additional 77,357 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Natera by 56.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock valued at $1,490,144,000 after acquiring an additional 3,795,315 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Natera by 9.9% in the 1st quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company’s stock valued at $1,041,055,000 after purchasing an additional 660,538 shares during the period. Geode Capital Management LLC increased its holdings in shares of Natera by 7.0% in the 2nd quarter. Geode Capital Management LLC now owns 2,552,725 shares of the medical research company’s stock valued at $430,640,000 after purchasing an additional 166,768 shares during the period. Finally, Invesco Ltd. boosted its holdings in shares of Natera by 13.7% during the first quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company’s stock worth $287,908,000 after purchasing an additional 245,719 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Price Performance

NASDAQ NTRA opened at $213.65 on Wednesday. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $215.81. The stock’s 50-day moving average is $183.03 and its two-hundred day moving average is $166.54. The firm has a market cap of $29.49 billion, a P/E ratio of -93.30 and a beta of 1.75.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The company had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. During the same period in the prior year, the company posted ($0.26) EPS. The business’s revenue was up 34.7% on a year-over-year basis. On average, equities analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Ratings Changes

NTRA has been the topic of several research reports. Stephens upped their price objective on shares of Natera from $197.00 to $235.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Piper Sandler upped their price target on shares of Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. UBS Group lifted their price objective on Natera from $218.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday. Barclays upped their target price on Natera from $210.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Finally, Canaccord Genuity Group raised their price target on Natera from $200.00 to $250.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Fifteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and a consensus price target of $220.29.

Insider Activity

In other news, CFO Michael Burkes Brophy sold 2,491 shares of Natera stock in a transaction that occurred on Tuesday, September 30th. The shares were sold at an average price of $162.05, for a total value of $403,666.55. Following the transaction, the chief financial officer owned 69,189 shares of the company’s stock, valued at $11,212,077.45. This trade represents a 3.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 160,703 shares of the company’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $199.96, for a total transaction of $32,134,171.88. Following the sale, the chief executive officer directly owned 144,816 shares of the company’s stock, valued at approximately $28,957,407.36. This represents a 52.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 223,336 shares of company stock worth $42,990,633. 5.63% of the stock is owned by company insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.